PipelineReview.com12h
Bayer starts Phase II clinical study with BAY 2927088 in metastatic or unresectable HER2 mutant solid tumors
First patient enrolled in the Phase II panSOHO basket trial; this is the third BAY 2927088 clinical trial in patients with HER2- activating mutations ...
PipelineReview.com12h
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
REDWOOD CITY, CA, USA I March 03, 2025 I Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve ...
PipelineReview.com12h
IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases
NEW YORK, NY, USA I March 03, 2025 I IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell ...
PipelineReview.com12h
CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody
SUZHOU, China I March 3, 2025 I CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and ...
PipelineReview.com12h
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
(Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and mAbxience (“mAbxience”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its ...
PipelineReview.com12h
Laekna Announces IND Approval of LAE120 (a Novel USP1 Inhibitor) for Treatment of Advanced Solid Tumors by FDA
LOS ANGELES, CA, USA I March 03, 2025 I Laekna (2105.HK) announced that the U.S. Food and Drug Administration (FDA) has approved the IND for LAE120, an ...
PipelineReview.com12h
FDA Approves Genentech’s TNKase®in Acute Ischemic Stroke in Adults
TNKase ® (tenecteplase) is the first stroke medicine approved by the FDA in nearly 30 years – – Single five-second intravenous bolus provides faster and simpler administr ...
PipelineReview.com1d
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing - ...
PipelineReview.com1d
DIOSynVax Presents Promising Bird Flu Vaccine Data in Late Breaker Session at the 2025 AAAAI Annual Meeting
SAN DIEGO, CA, USA I March 03, 2025 I DIOSynVax, a clinical-stage biotechnology company specializing in AI-leveraged vaccines has used this innovative ...
PipelineReview.com1d
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
NORTH CHICAGO, IL, USA and HØRSHOLM, Denmark I March 3, 2025 I AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical ...
PipelineReview.com1d
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
NEW HAVEN, CT, USA I March 3, 2025 I Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...
PipelineReview.com1d
Biond Biologics to Regain Full Rights to BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
Following positive results from the Phase 1 dose escalation study, BND-22 (SAR444881) is now being tested in Phase 2 trials as monotherapy for patients ...